Vectus Biosystems Names Dr Tara Speranza as CEO and CTO, Secures $791K to Boost VB0004 Phase Ib Trials

Dr Tara Speranza Strengthens Vectus Leadership to Drive Clinical Advancement

Effective 7 May 2026, Vectus Biosystems appointed Dr Tara Speranza as CEO and CTO. Dr Speranza brings over 20 years of experience encompassing scientific research, translational drug development, biotech commercialisation, strategic advisory, and capital markets. She had been consulting for Vectus since August 2025, ensuring continuity in understanding the company’s scientific platform, lead compound VB0004, and broader drug portfolio.

Her academic tenure includes senior research roles at the University of Sydney and University of Geneva, focusing on novel molecular targets and translating discoveries into therapeutic products. Notably, she led a commercial partnership with global pharma Servier that contributed to developing an anti-osteoporotic therapy. Transitioning from academia, Dr Speranza held investment and advisory roles supporting healthcare and biotech companies with valuation, capital raising, strategic positioning, and deal execution across early and late-stage assets.

Her appointment is expected to enhance Vectus’ capabilities as it advances into its next development phase. Dr Speranza’s combined scientific, commercial, and capital markets expertise will support VB0004’s progression through clinical trials and facilitate engagement with strategic, licensing, and commercial partners. Following her appointment, she hosted an investor webinar outlining Vectus’ strategic direction, corporate priorities, and development roadmap.

$791,000 Placement Accelerates VB0004 Phase Ib Clinical Trial Progress

In May 2026, Vectus completed a placement of 7,910,000 fully paid ordinary shares at $0.10 each, raising $791,000 gross. The placement involved sophisticated investors and excluded related parties. This capital infusion is strategically allocated to accelerate VB0004’s Phase Ib clinical trial, targeting fibrosis prevention and reversal in lungs, heart, and kidneys, alongside advancing other pipeline compounds and supporting working capital.

The placement coincided with the company’s leadership transition and preparations for increased engagement with US regulatory authorities, reflecting a focused approach to clinical development and operational efficiency.

Strategic Out-Licensing of VB4-P5 Grants Equity Stake in XORTX Therapeutics

In April 2026, Vectus out-licensed its VB4-P5 renal small molecule compound to Canadian Nasdaq-listed biotech XORTX Therapeutics Inc. The deal closed on 14 April 2026 after meeting all conditions. Vectus received 154,544 common shares (approximately 9.9% ownership) and 692,150 pre-funded warrants exercisable without further payment. Some securities are subject to lock-up periods of 45 to 180 days post-transaction.

XORTX acquired patents, IP, and data related to VB4-P5’s renal fibrosis and kidney disease applications. Vectus retained licenses for other therapeutic uses, preserving flexibility for future development. This structure allows Vectus to maintain exposure to VB4-P5’s future development and commercialisation without further funding obligations, enabling focus on VB0004’s advancement.

Cardinal Health Regulatory Services Appointed as US Regulatory Agent for FDA Engagements

After the June 2026 quarter, Vectus engaged Cardinal Health Regulatory Services (CHRS) as its US Regulatory Agent to manage FDA-facing activities for VB0004 and potentially other pipeline assets. CHRS will lead preparation and submission of regulatory communications, including Orphan Drug Designation requests, pre-IND interactions, and the formal IND application for VB0004 in idiopathic pulmonary fibrosis (IPF). CHRS is a leading US regulatory consultancy with deep FDA expertise, supporting Vectus’ strategic priority to advance VB0004 in the US market.

VB0004: A First-in-Class Antifibrotic Candidate Advancing Clinical Development

VB0004, Vectus’ lead compound, is a first-in-class antifibrotic agent demonstrating reversal of established fibrosis in preclinical models. It completed Phase Ia trials with a favorable safety and pharmacokinetic profile. The upcoming Phase Ib trial will further evaluate safety, tolerability, and preliminary efficacy in target patient populations.

The initial focus is idiopathic pulmonary fibrosis (IPF), a progressive lung disease with significant unmet medical needs. VB0004’s antifibrotic mechanism also holds potential for treating fibrosis in the heart and kidneys, supporting a multi-organ development strategy that could unlock multiple commercial pathways.

Financial Snapshot and Cost Controls Amid Clinical Progress

As of 30 June 2026, Vectus reported $718,000 cash on hand. Quarterly expenditures totaled $74,000, covering commercialisation, patent renewals, staff, and Phase I activities. Payments to related parties included $28,000 CEO salary and $11,000 in corporate services fees to Regional Corporate Services Pty Ltd, linked to Non-Executive Director Maurie Stang. The company has significantly lowered operating costs and focuses on licensing and collaborations. The May 2026 capital raise is expected to extend the cash runway and support VB0004 Phase Ib trial acceleration, reflecting disciplined capital management during clinical development.

Positioned for Licensing and Strategic Partnerships

Vectus is actively pursuing licensing and collaboration opportunities with larger pharma and biotech companies. The VB4-P5 out-licensing deal with XORTX exemplifies a strategy to maintain development exposure while reducing funding obligations. Leadership appointments and regulatory engagements prepare the company for potential partnerships around VB0004 and other assets.

Reduced operating costs provide flexibility for strategic transactions. Dr Speranza’s expertise in capital markets and deal execution enhances the company’s ability to identify and close strategic deals. Engagement of Cardinal Health Regulatory Services ensures professional FDA documentation and regulatory strategy, increasing appeal to prospective partners interested in fibrotic disease assets.

Orphan Drug Designation Pursuit and IPF Market Potential

Vectus is pursuing Orphan Drug Designation for VB0004 in IPF, leveraging CHRS to prepare the application. Orphan status in the US offers benefits including market exclusivity, clinical trial tax credits, and FDA fee waivers. IPF is a severe, progressive lung disease with limited treatments, representing a significant unmet need.

The antifibrotic approach targeting fibrosis prevention and reversal offers a differentiated mechanism from existing therapies. Achieving Orphan Drug Designation would provide regulatory advantages facilitating clinical development and future commercial positioning. The focus on IPF reflects a strategic regulatory and clinical development priority.

Clinical Development Risks and Challenges Ahead

As a clinical-stage biotech, Vectus faces risks including potential insufficient efficacy or safety of VB0004 in Phase Ib and later trials, which could delay or halt development. Preclinical success does not guarantee clinical outcomes, and Phase Ib introduces new uncertainties around dosing, safety, and efficacy. Failure to meet endpoints may require trial redesign or program discontinuation.

Financial constraints are notable; while the $791,000 placement supports near-term Phase Ib acceleration, further capital raises will likely be needed for later stages, potentially diluting shareholders. FDA interactions may also lead to additional requirements, increasing costs and timelines. Competitive advancements in fibrotic disease treatments could impact VB0004’s market positioning.

Upcoming Milestones and Investor Focus Areas

Investors should watch for progress in FDA pre-IND communications for VB0004 in IPF, supported by CHRS, and the subsequent IND application filing—critical regulatory milestones enabling Phase Ib trial initiation. Monitoring Orphan Drug Designation approval is also key, as it offers significant development and commercial incentives.

Advancement of VB0004 Phase Ib trials, including patient enrollment and interim safety and efficacy data, will provide important clinical validation. Updates on licensing or partnership discussions may reveal alternative funding or development pathways. Additionally, the value of Vectus’ equity stake in XORTX will indicate success of the VB4-P5 out-licensing strategy. Further clarity on pipeline development beyond VB0004 will inform long-term value creation prospects.